Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Dr. Christopher M. YeaChief Development Officer | -33,80k | 666,26k | Derivative Exercise and Sale | 7,07 - 26,78 | 229,92k | - |
| 2026-05-22 | Dr. Paul K. AudhyaChief Medical Officer | -2,24k | 59,96k | Derivative Exercise and Sale | 26,78 | 150,26k | - |
| 2026-05-22 | Ms. Nicole SweenyChief Commercial Officer | 3,51k | 0,00 | Derivative Exercise and Retained Stock | - | 59,29k | 6,29% |
| 2026-05-22 | Dr. Christopher M. YeaChief Development Officer | 1,16k | 0,00 | Derivative Exercise and Retained Stock | - | 229,92k | 0,51% |
| 2026-05-22 | Dr. Paul K. AudhyaChief Medical Officer | 2,76k | 0,00 | Derivative Exercise and Retained Stock | - | 150,26k | 1,87% |
| 2026-05-22 | Ms. Nicole SweenyChief Commercial Officer | -1,49k | 39,87k | Derivative Exercise and Sale | 26,78 | 59,29k | - |
| 2026-05-22 | Dr. Christopher M. YeaChief Development Officer | -1,97k | 52,65k | Derivative Exercise and Sale | 26,78 | 229,92k | - |
| 2026-05-21 | Mr. Benjamin L. PalleikoCEO & Director | 12,32k | 0,00 | Derivative Exercise and Retained Stock | - | 479,99k | 2,64% |
| 2026-05-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,93k | 292,65k | Derivative Exercise and Sale | 26,78 | 479,99k | - |
| 2026-05-21 | Ms. Nicole SweenyChief Commercial Officer | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 55,78k | 8,54% |
| 2026-05-21 | Ms. Nicole SweenyChief Commercial Officer | -1,86k | 49,85k | Derivative Exercise and Sale | 26,78 | 55,78k | - |
| 2026-05-21 | Dr. Christopher M. YeaChief Development Officer | 1,39k | 0,00 | Derivative Exercise and Retained Stock | - | 228,76k | 0,61% |
| 2026-05-21 | Dr. Christopher M. YeaChief Development Officer | -2,36k | 63,16k | Derivative Exercise and Sale | 26,78 | 228,76k | - |
| 2026-05-21 | Mr. Brian PiekosCFO | 3,51k | 0,00 | Derivative Exercise and Retained Stock | - | 21,66k | 19,34% |
| 2026-05-21 | Mr. Brian PiekosCFO | -1,49k | 39,88k | Derivative Exercise and Sale | 26,78 | 21,66k | - |
| 2026-05-21 | Dr. Paul K. AudhyaChief Medical Officer | 3,57k | 0,00 | Derivative Exercise and Retained Stock | - | 147,50k | 2,48% |
| 2026-05-21 | Dr. Paul K. AudhyaChief Medical Officer | -2,69k | 71,92k | Derivative Exercise and Sale | 26,78 | 147,50k | - |
| 2026-05-06 | Frazier Life Sciences Management, LPUnternehmen | -3,13M | 83,87M | Verkauf | 26,77 - 26,78 | 1,83M | -63,13% |
| 2026-05-17 | Dr. Christopher M. YeaChief Development Officer | 666,00 | 0,00 | Derivative Exercise and Retained Stock | - | 227,37k | 0,29% |
| 2026-05-17 | Dr. Christopher M. YeaChief Development Officer | -1,11k | 29,65k | Derivative Exercise and Sale | 26,76 | 227,37k | - |
| 2026-05-17 | Dr. Paul K. AudhyaChief Medical Officer | 1,39k | 0,00 | Derivative Exercise and Retained Stock | - | 143,93k | 0,97% |
| 2026-05-17 | Dr. Paul K. AudhyaChief Medical Officer | -1,03k | 27,62k | Derivative Exercise and Sale | 26,76 | 143,93k | - |
| 2026-05-17 | Mr. Benjamin L. PalleikoCEO & Director | 1,29k | 0,00 | Derivative Exercise and Retained Stock | - | 467,67k | 0,28% |
| 2026-05-17 | Mr. Benjamin L. PalleikoCEO & Director | -1,13k | 30,21k | Derivative Exercise and Sale | 26,76 | 467,67k | - |
| 2026-05-11 | Mr. Benjamin L. PalleikoCEO & Director | 3,80k | 0,00 | Derivative Exercise and Retained Stock | - | 466,38k | 0,82% |
| 2026-05-11 | Mr. Benjamin L. PalleikoCEO & Director | -3,32k | 88,73k | Derivative Exercise and Sale | 26,71 | 466,38k | - |
| 2026-04-16 | Ms. Nicole SweenyChief Commercial Officer | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 51,39k | 9,34% |
| 2026-04-16 | Ms. Nicole SweenyChief Commercial Officer | -1,86k | 37,64k | Derivative Exercise and Sale | 20,22 | 51,39k | - |
| 2026-04-16 | Dr. Paul K. AudhyaChief Medical Officer | 3,56k | 0,00 | Derivative Exercise and Retained Stock | - | 142,55k | 2,56% |
| 2026-04-16 | Dr. Paul K. AudhyaChief Medical Officer | -2,69k | 54,30k | Derivative Exercise and Sale | 20,22 | 142,55k | - |
| 2026-04-16 | Mr. Brian PiekosCFO | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 18,15k | 31,88% |
| 2026-04-16 | Mr. Brian PiekosCFO | -1,86k | 37,64k | Derivative Exercise and Sale | 20,22 | 18,15k | - |
| 2026-04-16 | Mr. Benjamin L. PalleikoCEO & Director | 10,76k | 0,00 | Derivative Exercise and Retained Stock | - | 462,58k | 2,38% |
| 2026-04-16 | Mr. Benjamin L. PalleikoCEO & Director | -9,55k | 193,07k | Derivative Exercise and Sale | 20,22 | 462,58k | - |
| 2026-03-25 | VR Management, LLCUnternehmen | -214,63k | 3,69M | Verkauf | 16,95 - 19,12 | 5,09M | -4,05% |
| 2026-03-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,93k | 0,00 | Derivative Exercise and Retained Stock | - | 451,82k | 2,02% |
| 2026-03-06 | Mr. Benjamin L. PalleikoCEO & Director | -6,69k | 107,63k | Derivative Exercise and Sale | 16,08 | 451,82k | - |
| 2026-02-21 | Dr. Paul K. AudhyaChief Medical Officer | 5,90k | 0,00 | Derivative Exercise and Retained Stock | - | 138,98k | 4,43% |
| 2026-02-21 | Dr. Paul K. AudhyaChief Medical Officer | -5,35k | 83,34k | Derivative Exercise and Sale | 15,57 | 138,98k | - |
| 2026-02-21 | Mr. Benjamin L. PalleikoCEO & Director | 13,22k | 0,00 | Derivative Exercise and Retained Stock | - | 442,88k | 3,08% |
| 2026-02-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,03k | 156,20k | Derivative Exercise and Sale | 15,57 | 442,88k | - |
| 2026-02-21 | Ms. Nicole SweenyChief Commercial Officer | 7,28k | 0,00 | Derivative Exercise and Retained Stock | - | 47,00k | 18,31% |
| 2026-02-22 | Ms. Nicole SweenyChief Commercial Officer | -3,98k | 61,88k | Derivative Exercise and Sale | 15,57 | 47,00k | - |
| 2026-02-21 | Dr. Christopher M. YeaChief Development Officer | 2,53k | 0,00 | Derivative Exercise and Retained Stock | - | 226,70k | 1,13% |
| 2026-02-21 | Dr. Christopher M. YeaChief Development Officer | -4,35k | 67,67k | Derivative Exercise and Sale | 15,57 | 226,70k | - |
| 2026-02-21 | Mr. Brian PiekosCFO | 3,23k | 0,00 | Derivative Exercise and Retained Stock | - | 13,76k | 30,71% |
| 2026-02-21 | Mr. Brian PiekosCFO | -1,77k | 27,51k | Derivative Exercise and Sale | 15,57 | 13,76k | - |
| 2026-02-17 | Dr. Paul K. AudhyaChief Medical Officer | 1,26k | 0,00 | Derivative Exercise and Retained Stock | - | 133,09k | 0,95% |
| 2026-02-17 | Dr. Paul K. AudhyaChief Medical Officer | -1,16k | 17,45k | Derivative Exercise and Sale | 15,00 | 133,09k | - |
| 2026-02-17 | Mr. Benjamin L. PalleikoCEO & Director | 1,38k | 0,00 | Derivative Exercise and Retained Stock | - | 429,67k | 0,32% |
| 2026-02-17 | Mr. Benjamin L. PalleikoCEO & Director | -1,04k | 15,57k | Derivative Exercise and Sale | 15,00 | 429,67k | - |
| 2026-02-17 | Dr. Christopher M. YeaChief Development Officer | 665,00 | 0,00 | Derivative Exercise and Retained Stock | - | 224,17k | 0,30% |
| 2026-02-17 | Dr. Christopher M. YeaChief Development Officer | -1,11k | 16,64k | Derivative Exercise and Sale | 15,00 | 224,17k | - |
| 2026-02-11 | Mr. Benjamin L. PalleikoCEO & Director | 3,77k | 0,00 | Derivative Exercise and Retained Stock | - | 428,29k | 0,89% |
| 2026-02-11 | Mr. Benjamin L. PalleikoCEO & Director | -3,35k | 52,66k | Derivative Exercise and Sale | 15,70 | 428,29k | - |
| 2025-12-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,33k | 0,00 | Derivative Exercise and Retained Stock | - | 424,52k | 2,00% |
| 2025-12-06 | Mr. Benjamin L. PalleikoCEO & Director | -7,29k | 120,42k | Derivative Exercise and Sale | 16,51 | 424,52k | - |
| 2025-11-21 | Ms. Nicole SweenyChief Commercial Officer | 7,44k | 0,00 | Derivative Exercise and Retained Stock | - | 39,73k | 23,03% |
| 2025-11-22 | Ms. Nicole SweenyChief Commercial Officer | -3,81k | 51,29k | Derivative Exercise and Sale | 13,45 | 39,73k | - |
| 2025-11-21 | Mr. Brian PiekosCFO | 10,53k | 0,00 | Derivative Exercise and Retained Stock | - | 10,53k | - |
| 2025-11-21 | Mr. Brian PiekosCFO | -4,47k | 60,14k | Derivative Exercise and Sale | 13,45 | 10,53k | - |
| 2025-11-21 | Dr. Christopher M. YeaChief Development Officer | 2,54k | 0,00 | Derivative Exercise and Retained Stock | - | 223,51k | 1,15% |
| 2025-11-21 | Dr. Christopher M. YeaChief Development Officer | -4,33k | 58,26k | Derivative Exercise and Sale | 13,45 | 223,51k | - |
| 2025-11-21 | Dr. Paul K. AudhyaChief Medical Officer | 5,95k | 0,00 | Derivative Exercise and Retained Stock | - | 131,83k | 4,73% |
| 2025-11-21 | Dr. Paul K. AudhyaChief Medical Officer | -5,30k | 71,24k | Derivative Exercise and Sale | 13,45 | 131,83k | - |
| 2025-11-21 | Mr. Benjamin L. PalleikoCEO & Director | 12,31k | 0,00 | Derivative Exercise and Retained Stock | - | 416,19k | 3,05% |
| 2025-11-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,94k | 147,15k | Derivative Exercise and Sale | 13,45 | 416,19k | - |
| 2025-11-20 | Dr. Christopher M. YeaChief Development Officer | 87,39k | 375,78 | Derivative Exercise and Retained Stock | 0,00 | 220,96k | 65,42% |
| 2025-11-17 | Mr. Benjamin L. PalleikoCEO & Director | 4,90k | 0,00 | Derivative Exercise and Retained Stock | - | 403,88k | 1,23% |
| 2025-11-17 | Mr. Benjamin L. PalleikoCEO & Director | -4,47k | 64,67k | Derivative Exercise and Sale | 14,48 | 403,88k | - |
| 2025-11-17 | Dr. Christopher M. YeaChief Development Officer | 1,52k | 0,00 | Derivative Exercise and Retained Stock | - | 133,57k | 1,15% |
| 2025-11-17 | Dr. Christopher M. YeaChief Development Officer | -2,68k | 38,85k | Derivative Exercise and Sale | 14,48 | 133,57k | - |
| 2025-11-17 | Dr. Paul K. AudhyaChief Medical Officer | 3,37k | 0,00 | Derivative Exercise and Retained Stock | - | 125,88k | 2,75% |
| 2025-11-17 | Dr. Paul K. AudhyaChief Medical Officer | -3,08k | 44,52k | Derivative Exercise and Sale | 14,48 | 125,88k | - |
| 2025-11-11 | Mr. Benjamin L. PalleikoCEO & Director | 3,79k | 0,00 | Derivative Exercise and Retained Stock | - | 398,98k | 0,96% |
| 2025-11-11 | Mr. Benjamin L. PalleikoCEO & Director | -3,33k | 38,44k | Derivative Exercise and Sale | 11,55 | 398,98k | - |
| 2025-11-01 | Frazier Life Sciences Management, LPUnternehmen | 973,45k | 0,00 | Kauf | - | 3,47M | 39,05% |
| 2025-09-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,33k | 0,00 | Derivative Exercise and Retained Stock | - | 395,19k | 2,15% |
| 2025-09-06 | Mr. Benjamin L. PalleikoCEO & Director | -7,29k | 115,54k | Derivative Exercise and Sale | 15,84 | 395,19k | - |
| 2025-08-22 | Ms. Nicole SweenyChief Commercial Officer | 3,52k | 0,00 | Derivative Exercise and Retained Stock | - | 32,29k | 12,23% |
| 2025-08-22 | Ms. Nicole SweenyChief Commercial Officer | -1,48k | 19,86k | Derivative Exercise and Sale | 13,42 | 32,29k | - |
| 2025-08-22 | Dr. Christopher M. YeaChief Development Officer | 1,17k | 0,00 | Derivative Exercise and Retained Stock | - | 132,05k | 0,89% |
| 2025-08-22 | Dr. Christopher M. YeaChief Development Officer | -1,95k | 26,22k | Derivative Exercise and Sale | 13,42 | 132,05k | - |
| 2025-08-22 | Dr. Paul K. AudhyaChief Medical Officer | 2,66k | 0,00 | Derivative Exercise and Retained Stock | - | 122,51k | 2,22% |
| 2025-08-22 | Dr. Paul K. AudhyaChief Medical Officer | -2,34k | 31,35k | Derivative Exercise and Sale | 13,42 | 122,51k | - |
| 2025-08-21 | Ms. Nicole SweenyChief Commercial Officer | 4,39k | 0,00 | Derivative Exercise and Retained Stock | - | 28,77k | 17,99% |
| 2025-08-21 | Ms. Nicole SweenyChief Commercial Officer | -1,86k | 24,65k | Derivative Exercise and Sale | 13,22 | 28,77k | - |
| 2025-08-21 | Dr. Christopher M. YeaChief Development Officer | 1,39k | 0,00 | Derivative Exercise and Retained Stock | - | 130,88k | 1,07% |
| 2025-08-21 | Dr. Christopher M. YeaChief Development Officer | -2,36k | 31,23k | Derivative Exercise and Sale | 13,22 | 130,88k | - |
| 2025-08-21 | Dr. Paul K. AudhyaChief Medical Officer | 3,31k | 0,00 | Derivative Exercise and Retained Stock | - | 119,84k | 2,84% |
| 2025-08-21 | Dr. Paul K. AudhyaChief Medical Officer | -2,94k | 38,90k | Derivative Exercise and Sale | 13,22 | 119,84k | - |
| 2025-08-21 | Mr. Benjamin L. PalleikoCEO & Director | 12,31k | 0,00 | Derivative Exercise and Retained Stock | - | 386,86k | 3,29% |
| 2025-08-21 | Mr. Benjamin L. PalleikoCEO & Director | -10,94k | 144,66k | Derivative Exercise and Sale | 13,22 | 386,86k | - |
| 2025-08-17 | Dr. Paul K. AudhyaChief Medical Officer | 3,51k | 0,00 | Derivative Exercise and Retained Stock | - | 116,53k | 3,10% |
| 2025-08-17 | Dr. Paul K. AudhyaChief Medical Officer | -2,94k | 38,76k | Derivative Exercise and Sale | 13,19 | 116,53k | - |
| 2025-08-17 | Dr. Christopher M. YeaChief Development Officer | 1,55k | 0,00 | Derivative Exercise and Retained Stock | - | 129,49k | 1,21% |
| 2025-08-17 | Dr. Christopher M. YeaChief Development Officer | -2,65k | 34,93k | Derivative Exercise and Sale | 13,19 | 129,49k | - |
| 2025-08-17 | Mr. Benjamin L. PalleikoCEO & Director | 4,95k | 0,00 | Derivative Exercise and Retained Stock | - | 374,55k | 1,34% |
| 2025-08-17 | Mr. Benjamin L. PalleikoCEO & Director | -4,41k | 58,14k | Derivative Exercise and Sale | 13,19 | 374,55k | - |
| 2025-07-09 | Mr. Benjamin L. PalleikoCEO & Director | -32,98k | 517,52k | Verkauf | 15,69 | 369,60k | -8,19% |
| 2025-07-09 | Dr. Christopher M. YeaChief Development Officer | -30,25k | 474,70k | Verkauf | 15,69 | 127,94k | -19,12% |
| 2025-06-06 | Mr. Benjamin L. PalleikoCEO & Director | 8,46k | 0,00 | Derivative Exercise and Retained Stock | - | 315,07k | 2,76% |
| 2025-06-06 | Mr. Benjamin L. PalleikoCEO & Director | -7,17k | 103,95k | Derivative Exercise and Sale | 14,50 | 315,07k | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
